References
- WheatleyLMTogiasAClinical practice. Allergic rhinitisN Engl J Med2015372545646325629743
- ChurchDChurchMScaddingGAllergic rhinitis: impact, diagnosis, treatment and managementClin Pharmacist201688
- LinnebergADam PetersenKHahn-PedersenJHammerbyESerup-HansenNBoxallNBurden of allergic respiratory disease: a systematic reviewClin Mol Allergy20161411227708552
- MayJRDolenWKManagement of allergic rhinitis: a review for the community pharmacistClin Ther201739122410241929079387
- LasserECThe multipotential pseudoantigenicity of X-ray contrast media. Pseudoantigen excess may downregulate the release of hypotensive mediatorsInt Arch Allergy Immunol2000123428229011146385
- LasserECX-ray contrast media mechanisms in the release of mast cell contents: understanding these leads to a treatment for allergiesJ Allergy20112011115
- AngjeliEGomesPLaneKJSteinLAbelsonMBTechnical and clinical validation of the Allergen BioCube® for Timothy grassImmun Inflamm Dis201751788428250927
- GomesPJLaneKJAngjeliESteinLAbelsonMBTechnical and clinical validation of an environmental exposure unit for ragweedJ Asthma Allergy2016921522128008277
- EllisAKNorthMLWalkerTSteacyLMEnvironmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challengeAnn Allergy Asthma Immunol2013111532332824125135
- DayJHBriscoeMPClarkRHEllisAKGervaisPOnset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitisAnn Allergy Asthma Immunol19977921631729291422
- DayJHBriscoeMPWelshAOnset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unitAnn Allergy Asthma Immunol19977965335409433370
- BerkowitzRBWoodworthGGLutzCOnset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unitAnn Allergy Asthma Immunol20028913845
- NIH ClinicalTrials.gov [webpage on the Internet]ORA, IncA pilot study evaluating the signs and symptoms of seasonal allergic rhinoconjunctivitis following exposure in the allergen bio-cube Available from: https://clini-caltrials.gov/ct2/show/NCT00985075Accessed September 12, 2018
- PasternakJJWilliamsonEEClinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologistMayo Clin Proc201287439040222469351
- FDAVisapaqueTM (iodixanol) Injection package insert 2003 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20351slr013_visipaque_lbl.pdf
- ShustermanDBalmesJAvilaPCMurphyMAMatovinovicEChlorine inhalation produces nasal congestion in allergic rhinitics without mast cell degranulationEur Respir J200321465265712762352
- VishwanathSBaroodyFMChaabanMRTopical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergenJ Allergy Clin Immunol2011128121922121414657
- BaroodyFMNaclerioRMNasal-ocular reflexes and their role in the management of allergic rhinoconjunctivitis with intranasal steroidsWorld Allergy Organ J201141 SupplS1S523283068
- NaclerioRIntranasal corticosteroids reduce ocular symptoms associated with allergic rhinitisOtolaryngol Head Neck Surg2008138212913918241703
- BaroodyFMLogothetisHVishwanathSBashirMDetineoMNaclerioRMEffect of intranasal fluticasone furoate and intraocular olopatadine on nasal and ocular allergen-induced symptomsAm J Rhinol Allergy20132714853